China's Biotech Surge: US Must Build, Not Restrict — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump hosted Xi Jinping in Washington last week — their first summit in a decade — but tariffs, Iran, and rare earth minerals dominated the agenda while biotechnology was sidelined.
- China's new five-year plan designates biomedicine a national "pillar industry," targeting 25% of global first-in-class drugs by 2030; the US currently produces such medicines at seven times China's rate.
- China plans to grow its innovative-drug industry 20% annually, and as of 2025 Chinese-designed medicines accounted for nearly 30% of drugs in development globally, up from under 7% a decade earlier.
- Chinese labs manufacture about 20% of the active ingredients used in medicines the FDA considers essential — a leverage point the authors warn Beijing could exploit in a future crisis.
- Blanket tariffs on drug ingredients and sweeping US restrictions on biotech partnerships would disrupt critical supply chains and cut American firms off from promising experimental medicines, the authors argue.
- U.S. biotech export controls risk backfiring as semiconductor restrictions did, spurring Chinese firms to build independent capabilities — the authors cite past surges in Chinese R&D and patenting driven by US restrictions.
- The authors propose four policy pillars: expand domestic and allied manufacturing, coordinate with Japan, South Korea, Europe, and India, ease investment in next-gen manufacturing, and protect federal research funding and STEM immigration.
Why it matters: If China captures 25% of first-in-class drug development by 2030 while already supplying 20% of FDA-essential active ingredients, Beijing gains meaningful leverage over US health and military readiness in a future crisis. The authors, both architects of past export controls, now contend restrictions alone will backfire as semiconductor curbs did — Washington must fund research and ally with partners to stay ahead.
Ask SkimNews
